Aequus Pharmaceuticals Stock Performance
| AQSZF Stock | USD 0.01 0 18.18% |
The firm shows a Beta (market volatility) of 2.11, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aequus Pharmaceuticals will likely underperform. At this point, Aequus Pharmaceuticals has a negative expected return of -1.12%. Please make sure to confirm Aequus Pharmaceuticals' information ratio, skewness, as well as the relationship between the Skewness and day typical price , to decide if Aequus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Aequus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 1.7 M | |
| Total Cashflows From Investing Activities | -508 K |
Aequus |
Aequus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1.50 in Aequus Pharmaceuticals on September 13, 2024 and sell it today you would lose (0.95) from holding Aequus Pharmaceuticals or give up 63.33% of portfolio value over 90 days. Aequus Pharmaceuticals is currently producing negative expected returns and takes up 8.4175% volatility of returns over 90 trading days. Put another way, 74% of traded otc stocks are less volatile than Aequus, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Aequus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aequus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Aequus Pharmaceuticals, and traders can use it to determine the average amount a Aequus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1332
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AQSZF |
Estimated Market Risk
| 8.42 actual daily | 74 74% of assets are less volatile |
Expected Return
| -1.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Aequus Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aequus Pharmaceuticals by adding Aequus Pharmaceuticals to a well-diversified portfolio.
Aequus Pharmaceuticals Fundamentals Growth
Aequus OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Aequus Pharmaceuticals, and Aequus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aequus OTC Stock performance.
| Return On Equity | -2.92 | |||
| Return On Asset | -0.42 | |||
| Profit Margin | (1.36) % | |||
| Operating Margin | (1.31) % | |||
| Current Valuation | 3.03 M | |||
| Shares Outstanding | 132.63 M | |||
| Price To Earning | (1.79) X | |||
| Price To Book | 32.78 X | |||
| Price To Sales | 1.44 X | |||
| Revenue | 2.71 M | |||
| EBITDA | (1.23 M) | |||
| Cash And Equivalents | 1.39 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 26.09 K | |||
| Debt To Equity | 1.39 % | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (1.17 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 4.35 M | |||
| Retained Earnings | (5.72 M) | |||
| Current Asset | 458 K | |||
| Current Liabilities | 704 K | |||
About Aequus Pharmaceuticals Performance
By analyzing Aequus Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Aequus Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aequus Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aequus Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Aequus Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 14 people.Things to note about Aequus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Aequus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Aequus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aequus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Aequus Pharmaceuticals has high historical volatility and very poor performance | |
| Aequus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Aequus Pharmaceuticals has accumulated 26.09 K in total debt with debt to equity ratio (D/E) of 1.39, which is about average as compared to similar companies. Aequus Pharmaceuticals has a current ratio of 0.76, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Aequus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Aequus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aequus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aequus to invest in growth at high rates of return. When we think about Aequus Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 2.71 M. Net Loss for the year was (1.81 M) with profit before overhead, payroll, taxes, and interest of 2.69 M. | |
| Aequus Pharmaceuticals has accumulated about 1.39 M in cash with (1.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Aequus Pharmaceuticals shares are held by company insiders |
- Analyzing Aequus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aequus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Aequus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aequus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aequus Pharmaceuticals' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Aequus Pharmaceuticals' otc stock. These opinions can provide insight into Aequus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Aequus OTC Stock analysis
When running Aequus Pharmaceuticals' price analysis, check to measure Aequus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aequus Pharmaceuticals is operating at the current time. Most of Aequus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aequus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aequus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aequus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |